Update date
31 Mar 2020
Shareable Research Card
This metric view shows ASND - Ascendis Pharma A/S goodwill history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest reported goodwill: €3,495,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Update date
31 Mar 2020
Page type
Metric history
Latest period
Q1 2020
SEC-backed company facts were refreshed from filings filed on 11 Feb 2026.
Benchmark Context
Ascendis Pharma A/S sits in the bottom quarter of the current goodwill sample.
Compared with
Compared with 49 companies reporting goodwill in EUR. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Goodwill is roughly flat versus the comparable prior period.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Latest period: Q1 2020. Period end: 31 Mar 2020. Units: EUR. Frequency: quarterly.
Goodwill is an SEC-reported metric from company XBRL facts.
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare latest available Goodwill levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Ascendis Pharma A/S appears at rank #46 in the latest comparison sample.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Sanofi (sny) | €41,300,000,000 | Instant - 31 Dec 2025 | Open Sanofi Goodwill |
| 2 | SAP SE (sap) | €29,014,000,000 | Instant - 31 Dec 2025 | Open SAP SE Goodwill |
| 3 | ORANGE (fnctf) | €23,775,000,000 | Instant - 31 Dec 2023 | Open ORANGE Goodwill |
| 4 | VODAFONE GROUP PUBLIC LTD CO (vod) | €20,514,000,000 | Instant - 31 Mar 2025 | Open VODAFONE GROUP PUBLIC LTD CO Goodwill |
| 5 | UNILEVER PLC (ul) | €17,709,000,000 | Instant - 31 Dec 2025 | Open UNILEVER PLC Goodwill |
| 6 | TELEFONICA S A (tefof) | €16,461,000,000 | Instant - 31 Dec 2024 | Open TELEFONICA S A Goodwill |
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q1 2020 | €3,495,000 | €0 | 0% | 31 Mar 2020 | 6-K | 19 May 2020 | 2020 | Q1 |
| Q4 2019 | €3,495,000 | €0 | 0% | 31 Dec 2019 | 6-K | 19 May 2020 | 2020 | Q1 |
| Q3 2019 | €3,495,000 | €0 | 0% | 30 Sep 2019 | 6-K | 18 Nov 2019 | 2019 | Q3 |
| Q2 2019 | €3,495,000 | €0 | 0% | 30 Jun 2019 | 6-K | 28 Aug 2019 | 2019 | Q2 |
| Q1 2019 | €3,495,000 | €0 | 0% | 31 Mar 2019 | 6-K | 30 May 2019 | 2019 | Q1 |
| Q4 2018 | €3,495,000 | €0 | 0% | 31 Dec 2018 | 20-F | 03 Apr 2020 | 2019 | FY |
| Q3 2018 | €3,495,000 | 30 Sep 2018 | 6-K | 28 Nov 2018 | 2018 | Q3 | ||
| Q2 2018 | €3,495,000 | 30 Jun 2018 | 6-K | 29 Aug 2018 | 2018 | Q2 | ||
| Q1 2018 | €3,495,000 | 31 Mar 2018 | 6-K | 30 May 2018 | 2018 | Q1 | ||
| Q4 2017 | €3,495,000 | €0 | 0% | 31 Dec 2017 | 20-F | 03 Apr 2020 | 2019 | FY |
| Q4 2016 | €3,495,000 | 31 Dec 2016 | 20-F | 03 Apr 2019 | 2018 | FY |